Stryker announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. The acquisition should strengthen Stryker's neurotechnology portfolio for tumor and stroke care.
NICO's BrainPath and Myriad products enable a treatment option for ICH with improved functional outcomes compared to guideline-based medical management alone, the current standard of care.
"The acquisition of NICO Corporation expands Stryker's portfolio of solutions for tumor resection and the treatment of intracerebral hemorrhage, the deadliest form of stroke," said Andy Pierce, group president, MedSurg and Neurotechnology, Stryker. "As a global leader in neurosurgical access and removal tools, this strategic addition enables us to deliver differentiated, minimally invasive approaches that will drive meaningful outcomes and improve the lives of patients worldwide."
